Welcome to our dedicated page for Ncs Multistage Hldgs SEC filings (Ticker: NCSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating sleeve sales data, frac-isolation backlog, or water-usage liabilities inside NCS Multistage’s dense disclosures can feel like hunting for a perforation in a 20-stage well. The company’s reports are rich with technical terms—pinpoint stimulation, coiled-tubing fracturing, stage isolation—that make traditional SEC research slow and error-prone.
Stock Titan solves this problem. Our AI reads every NCS Multistage SEC filing the moment it posts to EDGAR, then delivers plain-English answers investors actually search for: “NCS Multistage insider trading Form 4 transactions,� “NCS Multistage quarterly earnings report 10-Q filing,� and “understanding NCS Multistage SEC documents with AI.� Whether you need the latest 8-K material events explained or a NCS Multistage annual report 10-K simplified, one click opens an AI summary, key metrics table, and contextual risk flags.
All forms are covered in real time: 10-Ks for environmental obligations and impairment tests, 10-Qs for sleeve-installation revenue swings, 8-Ks for contract awards, and Form 4 insider data that highlight NCS Multistage executive stock transactions Form 4 during commodity up-cycles. Our platform also surfaces proxy statement compensation details and provides an NCS Multistage earnings report filing analysis that links cash-flow trends to North American rig counts. Stop scrolling through hundreds of pages; with Stock Titan you get NCS Multistage SEC filings explained simply—precise, searchable, and ready when you are.
NCS Multistage Holdings, Inc. (NCSM) filed a Form 144 indicating a proposed sale of 548 common shares through Morgan Stanley Smith Barney on or around 08/04/2025 via NASDAQ. The shares were originally acquired as restricted stock on 02/28/2025. At the stated market value of $16,440.44, the transaction represents roughly 0.02% of the company’s 2,540,849 outstanding shares. No prior insider sales were reported in the past three months, and the filer affirms no undisclosed material adverse information about the issuer.
The filing is routine and signals a modest liquidity event rather than a strategic shift. Given the tiny proportion of shares involved, the market impact should be negligible unless taken as a broader sentiment indicator of insider confidence.
NCS Multistage Holdings, Inc. (NCSM) filed a Form S-8 to register 250,000 additional shares of common stock (par $0.01) for issuance under its Amended & Restated 2017 Equity Incentive Plan. After this filing, a maximum 876,626 shares may be issued under the plan, inclusive of shares previously registered on four prior S-8 statements (2017, June 2020, December 2020, August 2023). All figures reflect the company’s 1-for-20 reverse stock split effective 1 Dec 2020.
The company is a non-accelerated filer and a smaller reporting company. Standard DGCL-based indemnification provisions, director exculpation (for directors only), and D&O insurance remain in place. Exhibits include the plan document (4.4), legal opinion (5.1), auditor consent (23.1) and filing-fee tables (107).
The registration enables NCSM to issue equity compensation without new capital inflow, potentially causing modest dilution but supporting employee retention and alignment.
NCSM’s Q2-25 10-Q shows a clear YoY turnaround. Revenue rose 23% to $36.5 mm, driven by a 46% jump in product sales that offset an 19% decline in service revenue. Consolidated gross profit improved $2.5 mm and the operating loss narrowed to $2.0 mm from $4.2 mm. A $1.0 mm deferred-tax benefit plus FX gains lifted net income attributable to NCS to $0.9 mm ($0.34 diluted EPS) versus a $3.1 mm loss (-$1.21) last year.
For the six months, revenue climbed 18% to $86.5 mm and net income swung to $5.0 mm ($1.84 diluted EPS). Canada contributed 49% of Q2 sales, the U.S. 37%, and other markets 14%.
Balance sheet. Cash remained healthy at $25.4 mm; NCS drew no amounts on its $35 mm ABL facility. Total debt consists solely of $7.7 mm of finance leases. Equity increased to $124.0 mm.
Cash flow. H1 operating cash inflow fell to $1.9 mm from $4.1 mm on higher working-capital needs; capex was modest at $0.7 mm.
Strategic update. On 31-Jul-25 NCS closed the $5.9 mm cash acquisition of Reservoir Metrics to expand tracer diagnostics, with an earn-out of up to $1.3 mm.
Risks & Outlook. Management cites stable Canadian activity, softer U.S. completions, potential international growth, and cost headwinds from steel/chemical tariffs. Ongoing Canadian patent appeals and U.S. litigation could affect future results but no gain/loss has been booked.
FAQ
What is the current stock price of Ncs Multistage Hldgs (NCSM)?
What is the market cap of Ncs Multistage Hldgs (NCSM)?
What does NCS Multistage Holdings Inc. specialize in?
What is the core technology behind NCS's offerings?
Who are the primary customers served by NCS?
How does NCS enhance operational efficiency?
In which markets does NCS operate?
What are the economic benefits of NCS's technology?
How does NCS support its customers beyond providing products?
How does NCS differentiate itself from competitors?
